Shots:

• Ionis to get $75M upfront plus $684M as development- regulatory- sales milestones- license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for conducting P-II trial for IONIS-FB-LRx in patients with Geographic Atrophy (GA)
• Under the agreement- Roche has option to license IONIS-FB-LRx post trial completion and will hold global development and commercialization rights
• IONIS-FB-LRx is an antisense drug used for reduction of Factor B(FB) in patients with GA and is developed by Ionis' LIgand Conjugated Antisense (LICA) technology

Ref: Ionis Pharma | Image: Roche